Cerebrotendinous Xanthomatosis Drives Recurrent Stroke After PFO Closure

Beyond structural defects in young adult stroke

Ischemic stroke in young adults often triggers a search for structural or embolic sources, yet the underlying pathology frequently involves complex genetic and metabolic drivers of premature atherosclerosis [1, 2]. While common findings like a patent foramen ovale (a persistent opening between the right and left atria) are often implicated in cryptogenic events, clinicians must remain vigilant for rare autosomal recessive disorders that mimic standard vascular risk factors [3, 4]. These conditions often present as part of a broader multisystem syndrome involving progressive white matter degeneration or atypical lipid deposition, such as the Achilles tendon xanthomas and bilateral dentate nucleus hyperintensities characteristic of cerebrotendinous xanthomatosis [5, 6]. Early identification of these metabolic pathways is essential, as specific genetic sterol disorders offer critical windows for targeted therapeutic intervention [7]. A recent case study of a 23-year-old man with recurrent stroke highlights how a common structural finding can mask a rare, treatable metabolic cause of vascular disease [8].

Recurrence despite structural intervention

The case report describes a 23-year-old man who experienced recurrent strokes, beginning with an event initially classified as cryptogenic. During the diagnostic evaluation for his first stroke, clinicians identified a patent foramen ovale (a persistent opening between the right and left atria of the heart). To assess the likelihood that this structural defect was the primary cause of the ischemia, the medical team utilized the Risk of Paradoxical Embolism score, a clinical tool that integrates factors such as young age and the absence of traditional vascular risk factors to estimate the probability of a patent foramen ovale-related stroke. The patient had a high Risk of Paradoxical Embolism score, suggesting a strong causal link that guided the clinical decision to pursue a permanent structural repair. Based on this high probability of paradoxical embolism, the patient underwent a patent foramen ovale closure procedure. Despite this mechanical intervention, he returned to the hospital three years later with new neurological deficits. Imaging confirmed a recurrent stroke, specifically an occlusion of the right M1 segment (the primary horizontal branch of the middle cerebral artery). The appearance of a second major vascular event in a young patient, occurring three years after the correction of a high-risk structural defect, indicated that the patent foramen ovale was likely an incidental finding rather than the primary driver of his underlying vasculopathy.

Vessel wall imaging and multisystem indicators

To investigate the mechanism behind the recurrent right M1 segment occlusion, the medical team utilized high-resolution magnetic resonance vessel wall imaging, a specialized MRI technique that visualizes the layers of the arterial wall rather than just the lumen. This advanced imaging demonstrated the presence of intracranial atherosclerotic plaque, a finding that contradicted the initial assumption of a purely embolic source. The identification of localized atherosclerosis in a 23-year-old patient necessitated a comprehensive re-evaluation of his clinical history to identify drivers of premature vascular aging. A detailed review provided critical clues pointing toward a systemic metabolic disorder. Clinicians discovered that the patient had suffered from chronic diarrhea since infancy, an often overlooked early gastrointestinal manifestation of certain lipid storage diseases. Additionally, the patient had a documented history of juvenile cataracts, a classic indicator of abnormal sterol metabolism. These multisystem symptoms suggested a chronic, progressive underlying pathology rather than an isolated structural cardiac defect. Physical examination further supported a diagnosis of a complex metabolic syndrome. The patient exhibited borderline intellectual functioning, suggesting long-standing neurological involvement. Neurological assessment revealed bilateral ankle clonus (involuntary, rhythmic muscle contractions associated with upper motor neuron dysfunction). Most significantly, the examination identified Achilles tendon xanthomas, which are localized fatty deposits within the tendons. These physical findings, combined with the imaging evidence of premature atherosclerosis, provided the clinical basis for pursuing genetic testing for rare metabolic conditions.

Metabolic diagnosis and therapeutic implications

The clinical suspicion of a systemic metabolic error was confirmed through neuroimaging and molecular analysis. A brain MRI exhibited characteristic bilateral dentate nucleus hyperintensities (bright signals in the cerebellar nuclei on T2-weighted or fluid-attenuated inversion recovery sequences). These imaging markers are highly suggestive of cerebrotendinous xanthomatosis (CTX), a rare autosomal recessive metabolic disorder caused by a deficiency in the mitochondrial enzyme sterol 27-hydroxylase. To provide definitive confirmation, the medical team conducted genetic testing, which identified pathogenic variants in the CYP27A1 gene. This genetic finding, coupled with the patient's clinical presentation of juvenile cataracts, chronic diarrhea, and tendon xanthomas, established a formal diagnosis of cerebrotendinous xanthomatosis. The identification of CTX in this patient explains the underlying mechanism of his vascular disease, as this metabolic disorder is known to cause premature atherosclerosis and ischemic stroke in young adults. In the absence of a metabolic diagnosis, the recurrent M1 segment occlusion might have been incorrectly attributed to a failure of the patent foramen ovale closure rather than an aggressive atherosclerotic process. For practicing physicians, this case underscores that early recognition of CTX enables targeted therapy (such as chenodeoxycholic acid replacement to normalize bile acid synthesis), which can halt the progression of neurological and vascular damage. Timely intervention is critical to improving patient outcomes and preventing further life-threatening ischemic events in individuals who present with atypical stroke etiologies.

References

1. Members AF, Reiner Ž, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal. 2011. doi:10.1093/eurheartj/ehr158

2. Pan-Lizcano R, Mariñas‐Pardo L, Núñez L, et al. Rare Variants in Genes of the Cholesterol Pathway Are Present in 60% of Patients with Acute Myocardial Infarction. International Journal of Molecular Sciences. 2022. doi:10.3390/ijms232416127

3. Masellis M, Sherborn K, Rosa‐Neto P, et al. Early-onset dementias: diagnostic and etiological considerations. Alzheimer s Research & Therapy. 2013. doi:10.1186/alzrt197

4. Liu M, Wang Y, Shi C, et al. Genetic spectrum and clinical features of adult leukoencephalopathies in a Chinese cohort. Annals of Clinical and Translational Neurology. 2023. doi:10.1002/acn3.51794

5. Liu L, Wang Y, Chen X, Li Y, Fang Y, Li CB. Pearls & Oy-sters: Stroke Recurrence After PFO Closure Uncovers Cerebrotendinous Xanthomatosis. Neurology. 2026. doi:10.1212/wnl.0000000000218061

6. Chapleau A, Perrier S, Durcan TM, Bernard G. A scoping review of stem cell models of leukodystrophies: advances in understanding pathophysiological mechanisms. npj Genomic Medicine. 2025. doi:10.1038/s41525-025-00533-0

7. Żukowska A, Król M, Kupnicka P, Bąk K, Janawa K, Chlubek D. Exploring Recent Developments in the Manifestation, Diagnosis, and Treatment of Patients with Smith–Lemli–Opitz Syndrome: From Molecular Pathways to Clinical Innovations. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146672

8. Liu L, Wang Y, Chen X, Li Y, Fang Y, Li C. Pearls & Oy-sters: Stroke Recurrence After PFO Closure Uncovers Cerebrotendinous Xanthomatosis.. Neurology. 2026. doi:10.1212/WNL.0000000000218061